Spero Therapeutics, Inc. — Director's Dealing 2020

Jun 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2020-06-22

Reporting Person: Mahadevia Ankit (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-22	Common Stock	M	2613	$5.90	Acquired	68430	Direct
2020-06-22	Common Stock	S	2613	$14.2996	Disposed	65817	Direct
2020-06-23	Common Stock	M	8045	$5.90	Acquired	73862	Direct
2020-06-23	Common Stock	S	8045	$14.3274	Disposed	65817	Direct
2020-06-24	Common Stock	M	3880	$5.90	Acquired	69697	Direct
2020-06-24	Common Stock	S	3880	$14.2834	Disposed	65817	Direct
2020-06-25	Common Stock	M	2642	$5.90	Acquired	68459	Direct
2020-06-25	Common Stock	S	2642	$14.2507	Disposed	65817	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-22	Stock Option (Right to Buy)	$5.90	M	2613	Disposed	2027-07-05	Common Stock (2613)	Direct
2020-06-23	Stock Option (Right to Buy)	$5.90	M	8045	Disposed	2027-07-05	Common Stock (8045)	Direct
2020-06-24	Stock Option (Right to Buy)	$5.90	M	3880	Disposed	2027-07-05	Common Stock (3880)	Direct
2020-06-25	Stock Option (Right to Buy)	$5.90	M	2642	Disposed	2027-07-05	Common Stock (2642)	Direct

Footnotes

F1: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares).

F2: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

F3: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.